Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future

References

• Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010;68(2):270-81
   PubMed Web of Science ®Google Scholar
• Bertram L, Tanzi RE. The genetics of Alzheimer’s disease. Prog Mol Biol Transl Sci 2012;107:79-100
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Singleton AB. Nature versus nurture: death of a dogma, and the road ahead. Neuron 2010;68(2):196-200
   PubMedGoogle Scholar
• Yu JT, Tan L, Hardy J. Apolipoprotein E in Alzheimer’s disease: an update. Annu Rev Neurosci 2014;37:79-100
   PubMed Web of Science ®Google Scholar
• Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer’s disease. Lancet Neurol 2013;12(1):92-104
   PubMed Web of Science ®Google Scholar
• Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013;9(2):106-18
   PubMed Web of Science ®Google Scholar
• Lu JX, Qiang W, Yau WM, et al. Molecular structure of β-amyloid fibrils in Alzheimer’s disease brain tissue. Cell 2013;154(6):1257-68
   PubMed Web of Science ®Google Scholar
• Schneider LS. Pharmacological treatment of Alzheimer’s disease. In: Hampel HCarillo MC, editors, Alzheimer’ disease – modernizing concept, biological diagnosis and therapy. Adv Biol Psychiatry Karger; Basel, Switzerland: 2012. p. 122-67
   Google Scholar
• Larson EB, Yaffe K, Langa KM. New insights into the dementia epidemic. N Engl J Med 2013;369(24):2275-7
   PubMed Web of Science ®Google Scholar
• Manton KC, Gu XL, Ukraintseva SV. Declining prevalence of dementia in the U.S. elderly population. Adv Gerontol 2005;16:30-7
   PubMedGoogle Scholar
• Langa KM, Larson EB, Karlawish JH, et al. Trends in the prevalence and mortality of cognitive impairment in the United States: is there evidence of a compression of cognitive morbidity? Alzheimers Dement 2008;4(2):134-44
   PubMed Web of Science ®Google Scholar
• Schrijvers EM, Verhaaren BF, Koudstaal PJ, et al. Is dementia incidence declining?: trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 2012;78(19):1456-63
   PubMedGoogle Scholar
• Qiu C, von Strauss E, Bäckman L, et al. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 2013;80(20):1888-94
   PubMed Web of Science ®Google Scholar
• Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 2013;382(9902):1405-12
   PubMed Web of Science ®Google Scholar
• Solomon A, Mangialasche F, Richard E, et al. Advances in the prevention of Alzheimer’s disease and dementia. J Intern Med 2014;275(3):229-50
   PubMed Web of Science ®Google Scholar
• Nisticò R, Pignatelli M, Piccinin S, et al. Targeting synaptic dysfunction in Alzheimer’s disease therapy. Mol Neurobiol 2012;46(3):572-87
   PubMed Web of Science ®Google Scholar
• Mangialasche F, Solomon A, Winblad B, et al. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol 2010;9(7):702-16
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992;256(5054):184-5
   PubMed Web of Science ®Google Scholar
• Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8(2):101-12
   PubMed Web of Science ®Google Scholar
• Findeis MA. Peptide inhibitors of beta amyloid aggregation. Curr Top Med Chem 2002;2(4):417-23
   PubMedGoogle Scholar
• Nakagami Y, Nishimura S, Murasugi T, et al. A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br J Pharmacol 2002;137(5):676-82
   PubMed Web of Science ®Google Scholar
• Walsh DM, Klyubin I, Shankar GM, et al. The role of cell-derived oligomers of Abeta in Alzheimer’s disease and avenues for therapeutic intervention. Biochem Soc Trans 2005;33(Pt 5):1087-90
   PubMedGoogle Scholar
• Gervais F, Paquette J, Morissette C, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007;28(4):537-47
   PubMed Web of Science ®Google Scholar
• Gauthier S, Aisen PS, Ferris SH, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer’s disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging 2009;13(6):550-7
   PubMedGoogle Scholar
• Amijee H, Scopes DI. The quest for small molecules as amyloid inhibiting therapies for Alzheimer’s disease. J Alzheimers Dis 2009;17(1):33-47
   PubMedGoogle Scholar
• Tomita T. Secretase inhibitors and modulators for Alzheimer’s disease treatment. Expert Rev Neurother 2009;9(5):661-79
   PubMed Web of Science ®Google Scholar
• Merck Initiates Phase II/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer’s Disease. Available from: www.mercknewsroom.com/press-release/research-and-development-news/merck-initiates-phase-iiiii-study-investigational-bace-i
   Google Scholar
• Ittner LM, Götz J. Amyloid-β and tau–a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci 2011;12(2):65-72
   PubMed Web of Science ®Google Scholar
• Ma T, Hoeffer CA, Capetillo-Zarate E, et al. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer’s disease. PLoS One 2010;5(9): pii: e12845
   Google Scholar
• Alvarez A, Toro R, Cáceres A, Maccioni RB. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett 1999;459(3):421-6
   PubMedGoogle Scholar
• Wang Q, Walsh DM, Rowan MJ, et al. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 2004;24(13):3370-8
   PubMedGoogle Scholar
• Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011;68(8):853-61
   PubMed Web of Science ®Google Scholar
• Fleisher AS, Truran D, Mai JT, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 2011;77(13):1263-71
   PubMed Web of Science ®Google Scholar
• Hampel H, Ewers M, Bürger K, et al. Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 2009;70(6):922-31
   PubMed Web of Science ®Google Scholar
• Wischik CM, Edwards PC, Lai RY, et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 1996;93(20):11213-18
   PubMed Web of Science ®Google Scholar
• Ginimuge PR, Jyothi SD. Methylene blue: revisited. J Anaesthesiol Clin Pharmacol 2010;26(4):517-20
   PubMedGoogle Scholar
• Necula M, Breydo L, Milton S, et al. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry 2007;46(30):8850-60
   PubMed Web of Science ®Google Scholar
• Oz M, Lorke DE, Petroianu GA. Methylene blue and Alzheimer’s disease. Biochem Pharmacol 2009;78(8):927-32
   PubMed Web of Science ®Google Scholar
• Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem Pharmacol 2014;88(4):529-39
   PubMed Web of Science ®Google Scholar
• Piau A, Nourhashémi F, Hein C, et al. Progress in the development of new drugs in Alzheimer’s disease. J Nutr Health Aging 2011;15(1):45-57
   PubMedGoogle Scholar
• Herrup K. Current conceptual view of Alzheimer’s Disease. In: Hampel HCarillo MC, editors Alzheimer’ disease – modernizing concept, biological diagnosis and therapy. Adv Biol Psychiatry Karger; Basel, Switzerland: 2012. 30-48
   Google Scholar
• Bartus RT, Dean RL3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217(4558):408-14
   PubMed Web of Science ®Google Scholar
• Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000;163(2):495-529
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 2003;26(4):233-42
   PubMed Web of Science ®Google Scholar
• Revesz T, Ghiso J, Lashley T, et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003;62(9):885-98
   PubMedGoogle Scholar
• de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002;33(4):1152-62
   PubMed Web of Science ®Google Scholar
• Bell RD, Winkler EA, Singh I, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012;485(7399):512-16
   PubMed Web of Science ®Google Scholar
• Woodling NS, Wang Q, Priyam PG, et al. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci 2014;34(17):5882-94
   PubMedGoogle Scholar
• Dandrea MR, Reiser PA, Gumula NA, et al. Application of triple immunohistochemistry to characterize amyloid plaque-associated inflammation in brains with Alzheimer’s disease. Biotech Histochem 2001;76(2):97-106
   PubMedGoogle Scholar
• Delrieu J, Ousset PJ, Caillaud C, Vellas B. ‘Clinical trials in Alzheimer’s disease’: immunotherapy approaches. J Neurochem 2012;120(Suppl 1):186-93
   PubMedGoogle Scholar
• Vellas B, Carrillo MC, Sampaio C, et al. Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement 2013;9(4):438-44
   PubMed Web of Science ®Google Scholar
• Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011;3(111):111cm33
   PubMed Web of Science ®Google Scholar
• Golde TE, Schneider LS, Koo EH. Anti-Aβ therapeutics in Alzheimer’s disease: the need for a paradigm shift. Neuron 2011;69(2):203-13
   PubMed Web of Science ®Google Scholar
• Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9(7):560-74
   PubMed Web of Science ®Google Scholar
• Kozauer N, Katz R. Regulatory Innovation and Drug Development for Early-Stage Alzheimer’s Disease. N Engl J Med 2013;368(13):1169-71
   PubMedGoogle Scholar
• Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014;13(6):614-29
   PubMed Web of Science ®Google Scholar
• Brayne C. A population perspective on the IWG-2 research diagnostic criteria for Alzheimer’s disease. Lancet Neurol 2014;13(6):532-4
   PubMedGoogle Scholar
• Schneider LS. Rethinking the Food and Drug Administration’s 2013 guidance on developing drugs for early-stage Alzheimer’s disease. Alzheimers Dement 2014;10(2):247-250
   PubMedGoogle Scholar
• Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med 2014;275(3):251-83
   PubMed Web of Science ®Google Scholar
• Galimberti D, Ghezzi L, Scarpini E. Immunotherapy against amyloid pathology in Alzheimer’s disease. J Neurol Sci 2013;333(1-2):50-4
   PubMed Web of Science ®Google Scholar
• Schroeter S, Khan K, Barbour R, et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci 2008;28(27):6787-93
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6(8):916-19
   PubMed Web of Science ®Google Scholar
• Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008;14(8):837-42
   PubMed Web of Science ®Google Scholar
• Buttini M, Masliah E, Barbour R, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease. J Neurosci 2005;25(40):9096-101
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64(9):1553-62
   PubMed Web of Science ®Google Scholar
• Miller VM, Gouvion CM, Davidson BL, Paulson HL. Targeting Alzheimer’s disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res 2004;32(2):661-8
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73(24):2061-70
   PubMed Web of Science ®Google Scholar
• Bapineuzumab in patients with mild to moderate Alzheimer’s disease (ApoE4 Non-Carrier). Available from: http://clinicaltrials.gov/ct2/show/NCT00574132
   Google Scholar
• Bapineuzumab in patients with mild to moderate Alzheimer’s disease (ApoE4 Carrier). Available from: http://clinicaltrials.gov/show/NCT00575055
   Google Scholar
• Study evaluating the efficacy and safety of bapineuzumab in Alzheimer disease Patients. Available from: http://clinicaltrials.gov/ct2/show/NCT00667810
   Google Scholar
• study evaluating the safety and efficacy of bapineuzumab in Alzheimer disease Patients. Available from: http://clinicaltrials.gov/ct2/show/NCT00676143
   Google Scholar
• Pfizer Press Release. Pfizer announces topline results of first of four studies in bapineuzumab phase 3 program. July 23, 2012. Available from: http://press.pfizer.com/press-release/pfizer-announces-topline-results-first-four-studies-bapineuzumab-phase-3-program
   Google Scholar
• Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370(4):322-33
   PubMed Web of Science ®Google Scholar
• Investor Village. Available from: www.investorvillage.com/mbthread.asp?mb=160&tid=13153147&showall=1
   Google Scholar
• DeMattos RB, Racke MM, Gelfanova V, et al. Identification, characterization, and comparison of amino-terminally truncated Aβ42 peptides in Alzheimer’s disease brain tissue and in plasma from Alzheimer’s patients receiving solanezumab immunotherapy treatment. Alzheimers Dement 2009;5(4):P156-7; Abstract O4-04-02
   Google Scholar
• Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33(2):67-73
   PubMed Web of Science ®Google Scholar
• Walsh DM, Selkoe DJ. Aβ oligomers – a decade of discovery. J Neurochem 2007;101(5):1172-84
   PubMed Web of Science ®Google Scholar
• Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat Neurosci 2002;5(5):452-7
   PubMed Web of Science ®Google Scholar
• Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement 2012;8(4):261-71
   PubMed Web of Science ®Google Scholar
• Effect of LY2062430 on the progression of Alzheimer’s disease (EXPEDITION). Available from: http://clinicaltrials.gov/show/NCT00905372
   Google Scholar
• Effect of LY2062430 on the Progression of Alzheimer’s Disease (EXPEDITION2). Available from: http://clinicaltrials.gov/show/NCT00904683
   Google Scholar
• Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370(4):311-21
   PubMed Web of Science ®Google Scholar
• Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S13-21
   Web of Science ®Google Scholar
• Lilly Press Release. Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer’s Disease. August 24. 2012. Available from: https://investor.lilly.com/releasedetail.cfm?ReleaseID=702211
   Google Scholar
• Racke MM, Boone LI, Hepburn DL, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β. J Neurosci 2005;25(3):629-36
   PubMedGoogle Scholar
• Lilly Press release. lily announces detailed results of the Phase 3 Solanezumab EXPEDITION Studies Following a Presentation of the Independent Analyses by the Alzheimer’s Disease Cooperative Study (ADCS). October 8, 2012. Available from: https://investor.lilly.com/releasedetail.cfm?ReleaseID=711933
   Google Scholar
• Keller DM. solanezumab moderates cognitive decline in Alzheimer’s. 2012. Available from: www.medscape.com/viewarticle/772476
   Google Scholar
• continued safety monitoring of solanezumab in Alzheimer’s Disease (EXPEDITION EXT). Available from: http://clinicaltrials.gov/show/NCT01127633
   Google Scholar
• Lilly Press Release. Lilly provides update on next steps for Solanezumab. December 12, 2012. Available from: https://investor.lilly.com/releasedetail.cfm?ReleaseID=726309
   Google Scholar
• Progress of Mild Alzheimer’s disease in participants on solanezumab versus Placebo (EXPEDITION 3). Available from: http://clinicaltrials.gov/ct2/show/NCT01900665
   Google Scholar
• Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol 2013;9(1):54-8
   PubMedGoogle Scholar
• Sperling R, Donohue M, Aisen P. The A4 trial: anti-amyloid treatment of asymptomatic Alzheimer’s disease. Alzheimers Dement 2012;8(4):P425-6; Abstract F3-04-01
   Google Scholar
• Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02008357
   Google Scholar
• Sarazin M, Dorothée G, de Souza LC, Aucouturier P. Immunotherapy in Alzheimer’s disease: do we have all the pieces of the puzzle? Biol Psychiatry 2013;74(5):329-32
   PubMedGoogle Scholar
• Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurol 1992;42(3 Pt 1):631-9
   PubMed Web of Science ®Google Scholar
• Giannakopoulos P, Herrmann FR, Bussière T, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology 2003;60(9):1495-500
   PubMed Web of Science ®Google Scholar
• Nagy Z, Esiri MM, Jobst KA, et al. Relative roles of plaques and tangles in the dementia of Alzheimer’s disease: correlations using three sets of neuropathological criteria. Dementia 1995;6(1):21-31
   PubMedGoogle Scholar
• Giacobini E, Gold G. Alzheimer disease therapy–moving from amyloid-beta to tau. Nat Rev Neurol 2013;9(12):677-86
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82(4):239-59
   PubMed Web of Science ®Google Scholar
• Oddo S, Vasilevko V, Caccamo A, et al. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic plaques and tangles. J Biol Chem 2006;281(51):39413-23
   PubMed Web of Science ®Google Scholar
• Oddo S, Billings L, Kesslak JP, et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43(3):321-32
   PubMed Web of Science ®Google Scholar
• Rosenmann H, Grigoriadis N, Karussis D, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 2006;63(10):1459-67
   PubMedGoogle Scholar
• Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse reduces brain pathology with associated functional improvements. J Neurosci 2007;27(34):9115-29
   PubMed Web of Science ®Google Scholar
• Novak M. Tau vaccine: active immunization with a misfolded tau protein attenuates tau pathology in the transgenic rat model of tauopathy. Alzheimers Dement 2009;5(4):P93; Abstract S2-01-02
   PubMedGoogle Scholar
• Bi M, Ittner A, Ke YD, et al. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 2011;6(12):e26860
   PubMedGoogle Scholar
• Chai X, Wu S, Murray TK, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 2011;286(39):34457-67
   PubMed Web of Science ®Google Scholar
• Troquier L, Caillierez R, Burnouf S, et al. Targeting phospho-Ser422 by active Tau immunotherapy in the THYTTau22 mouse model: a suitable therapeutic approach. Curr Alz Res 2012;9(4):397-405
   PubMed Web of Science ®Google Scholar
• Novak M. Tau transgenic rat model and response to tau vaccine. Alzheimers Dement 2010;6(4):S118; Abstract F3-02-03
   PubMedGoogle Scholar
• Yoshiyama Y, Lee VM, Trojanowski JQ. Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry 2013;84(7):784-95
   PubMed Web of Science ®Google Scholar
• Hochgräfe K, Sydow A, Mandelkow EM. Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology. FEBS J 2013;280(18):4371-81
   PubMed Web of Science ®Google Scholar
• Zhang B, Maiti A, Shively S, et al. Microtubule-binding drugs offset tau sequestration by stabilizing mictrotubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 2005;102(1):227-31
   PubMed Web of Science ®Google Scholar
• Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986;83(13):4913-17
   PubMed Web of Science ®Google Scholar
• Wischik C, Staff R. Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitory therapy. J Nutr Health Aging 2009;13(4):367-9
   PubMed Web of Science ®Google Scholar
• Macdonald A, Briggs K, Poppe M, et al. A feasibility and tolerability study of lithium in Alzheimer’s disease. Int J Geriat Psychiatry 2008;23(7):704-11
   PubMedGoogle Scholar
• Villemagne VL, Okamura N. In vivo tau imaging: obstacles and progress. Alzheimers Dement 2014;10(3 Suppl):S254-64
   PubMed Web of Science ®Google Scholar
• Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 2013;369(4):341-50
   PubMed Web of Science ®Google Scholar
• Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26(Suppl 3):321-9
   PubMed Web of Science ®Google Scholar
• Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012;367(9):795-804
   PubMed Web of Science ®Google Scholar
• Ness S, Rafii M, Aisen P, et al. Down’s syndrome and Alzheimer’s disease: towards secondary prevention. Nat Rev Drug Discov 2012;11(9):655-6
   PubMedGoogle Scholar
• Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3):280-92
   PubMed Web of Science ®Google Scholar
• Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014;6(228): 228fs213
   Google Scholar
• Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 2014;71(8):961-70
   PubMed Web of Science ®Google Scholar
• Shoup TM, Yokell DL, Rice PA, et al. A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J Labelled Comp Radiopharm 2013;56(14):736-40
   PubMedGoogle Scholar
• Guidance for industry Alzheimer’s Disease: developing drugs for the treatment of early stage disease. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf
   Google Scholar
• Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3):270-9
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6(8):734-46
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010;9(11):1118-27
   PubMed Web of Science ®Google Scholar
• Morris JC, Blennow K, Froelich L, et al. Harmonized diagnostic criteria for Alzheimer’s disease: recommendations. J Intern Med 2014;275(3):204-13
   PubMedGoogle Scholar
• Hampel H, Carrillo MC. Alzheimer’s disease – modernizing concept, biological diagnosis and therapy. Advances in biological psychiatry. Volume 28. 1st edition. Karger; Basel, Switzerland: 2012
   Google Scholar
• Lista S, Garaci FG, Ewers M, et al. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease. Alzheimers Dement 2014;10(3):381-92
   PubMedGoogle Scholar
• Feldman HH, Haas M, Gandy S, et al. Alzheimer’s disease research and development: a call for a new research roadmap. Ann N Y Acad Sci 2014;1313:1-16
   PubMedGoogle Scholar
• Noel-Storr AH, Flicker L, Ritchie CW, et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimers Dement 2013;9(3):e96-e105
   Google Scholar
• Mattsson N, Andreasson U, Persson S, et al. CSF biomarker variability in the Alzheimer’s association quality control program. Alzheimers Dement 2013;9(3):251-61
   PubMed Web of Science ®Google Scholar
• Broich K, Schlosser-Weber G, Weiergräber M, Hampel H. Regulatory requirements on clinical trials in Alzheimer’s Disease. In: . and Hampel HCarillo MC, editors. Alzheimer’ Disease – Modernizing Concept, Biological Diagnosis and Therapy. Adv Biol Psychiatry Karger; Basel, Switzerland: 2012. 168-78
   Google Scholar
• Cortes-Blanco A, Prieto-Yerro C, Martinez-Lazaro R, et al. Florbetapir (18F) for Brain Amyloid Imaging - Highlights on the European marketing Approval. Alzheimers Dement 2014;10(5 Suppl):S395-9
   Google Scholar
• Chételat G, La Joie R, Villain N, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer’s disease. Neuroimage Clin 2013;2:356-65
   PubMed Web of Science ®Google Scholar
• Sperling R, Johnson K. Biomarkers of Alzheimer disease: current and future applications to diagnostic criteria. Continuum (Minneap Minn) 2013;19(2 Dementia):325-38
   PubMedGoogle Scholar
• Vandenberghe R, Adamczuk K, Dupont P, et al. Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer’s disease. Neuroimage Clin 2013;2:497-511
   PubMed Web of Science ®Google Scholar
• Richard E, Schmand BA, Eikelenboom P, Van Gool WA. Alzheimer’s Disease Neuroimaging Initiative. MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer’s disease in patients with mild cognitive impairment: a diagnostic accuracy study. BMJ Open 2013;3(6):pii: e002541
   Google Scholar
• Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol 2011;10(9):819-28
   PubMed Web of Science ®Google Scholar
• Daviglus ML, Plassman BL, Pirzada A, et al. Risk factors and preventive interventions for Alzheimer disease: state of the science. Arch Neurol 2011;68(9):1185-90
   PubMed Web of Science ®Google Scholar
• Mangialasche F, Kivipelto M, Solomon A, Fratiglioni L. Dementia prevention: current epidemiological evidence and future perspective. Alzheimers Res Ther 2012;4(1):6
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Solomon A, Ahtiluoto S, et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimers Dement 2013;9(6):657-65
   PubMed Web of Science ®Google Scholar
• Richard E, Van den Heuvel E, Moll van Charante EP, et al. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord 2009;23(3):198-204
   PubMedGoogle Scholar
• Carrie I, van Kan GA, Gillette-Guyonnet S, et al. Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). J Nutr Health Aging 2012;16(4):355-9
   PubMedGoogle Scholar
• Gillette-Guyonnet S, Andrieu S, Dantoine T, et al. Commentary on ‘A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.’ The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer’s disease. Alzheimers Dement 2009;5(2):114-21
   PubMedGoogle Scholar
• Finnish geriatric intervention study to prevent cognitive impairment and Disability (FINGER). Available from: http://clinicaltrials.gov/show/NCT01041989
   Google Scholar
• Kivipelto M, Ngandu T, Laatikainen T, et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006;5(9):735-41
   PubMed Web of Science ®Google Scholar
• Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 1989;39(9):1159-65
   PubMed Web of Science ®Google Scholar
• Omega-3 Fatty Acids and/or Multi-domain Intervention in the Prevention of Age-related Cognitive Decline (MAPT). Available from: http://clinicaltrials.gov/show/NCT00672685
   Google Scholar
• Prevention of Dementia by Intensive Vascular Care. Available from: http://controlled-trials.com/ISRCTN29711771
   Google Scholar
• EDPI. Available from: www.edpi.org/
   Google Scholar
• HATICE. Available from: www.hatice.eu/
   Google Scholar
• Ewers M, Sperling RA, Klunk WE, et al. Neuroimaging markers for the prediction and early diagnosis of Alzheimer’s disease dementia. Trends Neurosci 2011;34(8):430-42
   PubMedGoogle Scholar
• Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12(10):957-65
   PubMed Web of Science ®Google Scholar
• Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013;80(19):1784-91
   PubMedGoogle Scholar
• Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274(5284):99-102
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400(6740):173-7
   PubMed Web of Science ®Google Scholar
• Schenk D. Amyloid-beta immunotherapy for Alzheimer’s disease: the end of the beginning. Nat Rev Neurosci 2002;3(10):824-8
   PubMed Web of Science ®Google Scholar
• Aisen PS, Vellas B. Passive immunotherapy for Alzheimer’s disease: what have we learned, and where are we headed? J Nutr Health Aging 2013;17(1):49-50
   PubMedGoogle Scholar
• Gerald Z, Ockert W. Alzheimer’s disease market: hope deferred. Nat Rev Drug Discov 2013;12(1):19-20
   PubMed Web of Science ®Google Scholar
• Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer’s Disease. Available from: http://clinicaltrials.gov/ct2/show/NCT00299988
   Google Scholar
• Baxter press release. baxter announces topline results of Phase III Study of Immunoglobulin for Alzheimer’s Disease. May 07. 2013. Available from: www.baxter.com/press_room/press_releases/2013/05_07_13_gap_study.html
   Google Scholar
• Bowman Rogers M. Gammagard™ Misses Endpoints in Phase 3 Trial. May 08 2013. Available from: www.alzforum.org/new/detail.asp?id=3485
   Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353-6
   PubMed Web of Science ®Google Scholar
• Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 2012;488(7409):96-9
   PubMed Web of Science ®Google Scholar
• Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer’s disease. Nat Rev Drug Discov 2013;12(4):324
   PubMed Web of Science ®Google Scholar
• Strobel G. Collaborative Umbrella CAPs Three Prevention Trial Initiatives. August 07 2012. Available from: www.alzforum.org/new/detail.asp?id=3232
   Google Scholar
• Stephenson D. Alzheimer’s disease from researcher to caregiver: a personal journey and call to action. Expert Rev Neurother 2014;14(5):465-7
   PubMed Web of Science ®Google Scholar
• Misgeld T, Lichtenthaler SF, Dichgans M. Between new genetic discoveries and large randomized trials–neurological research in the era of systems medicine. EMBO Rep 2013;14(6):489-92
   PubMedGoogle Scholar
• Hampel H, Lista S, Khachaturian ZS. Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 2012;8(4):312-36
   PubMed Web of Science ®Google Scholar
• Hampel H, Lista S. Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge. Nat Rev Neurol 2012;8(11):598-600
   PubMedGoogle Scholar
• Orešič M, Lötjönen J, Soininen H. Systems medicine and the integration of bioinformatic tools for the diagnosis of Alzheimer’s disease. Genome Med 2009;1(11):83
   PubMedGoogle Scholar
• A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease. Available from: http://clinicaltrials.gov/ct2/show/NCT01767311
   Google Scholar
• Multiple Dose Study of BIIB037 (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer’s Disease. Available from: www.clinicaltrials.gov/ct2/show/NCT01677572
   Google Scholar
• Clinicaltrials. Available from: www.clinicaltrials.gov
   Google Scholar
• European Union Clinical Trials Register. Available from: www.clinicaltrialsregister.eu
   Google Scholar
• ALOIS. Available from: www.medicine.ox.ac.uk/alois
   Google Scholar
• ANZCTR. Available from: www.anzctr.org.au
   Google Scholar
• ALZ FORUM. Available from: www.alzgene.org
   Google Scholar